Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Alzheimer's & Dementia

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2016.09.014PMID 27870940PMCID PMC5218961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population‐based elderly cohort

  2016cited by this paper
• Translational biomaterials-the journey from the bench to the market-think 'product'.

  2016influential reference
• Exosomes as new diagnostic tools in CNS diseases.

  2016cited by this paper
• Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals

  2016cited by this paper
• P3‐152: Levels of TAU Protein in Plasma are Associated with Neurodegeneration and Cognitive Function in a Population‐Based Elderly Cohort

  2016cited by this paper
• Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers

  2016cited by this paper
• A blood screening test for Alzheimer's disease

  2016influential reference
• PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.

  2016cited by this paper
• Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy

  2016cited by this paper
• Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly

  2016cited by this paper
• Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease.

  2016cited by this paper
• Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

  2016cited by this paper
• Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

  2016cited by this paper
• Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders

  2016cited by this paper
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2016cited by this paper
• Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

  2016cited by this paper
• Exosomes in Alzheimer's disease.

  2016cited by this paper
• Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease

  2016cited by this paper
• Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

  2016cited by this paper
• Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile

  2016cited by this paper
• Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

  2015cited by this paper
• Screening for Alzheimer’s Disease

  2015cited by this paper
• Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study

  2015cited by this paper
• Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging

  2015cited by this paper
• Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges

  2015cited by this paper
• Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?

  2015cited by this paper
• Revolutionizing Alzheimer's disease and clinical trials through biomarkers

  2015cited by this paper
• PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

  2015cited by this paper
• Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.

  2015cited by this paper
• Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research

  2015cited by this paper
• Innovative diagnostic tools for early detection of Alzheimer's disease

  2015cited by this paper
• The use of biomarkers in human pharmacology (Phase I) studies.

  2015cited by this paper
• Plasma proteins predict conversion to dementia from prodromal disease

  2014cited by this paper
• Plasma phospholipids identify antecedent memory impairment in older adults

  2014cited by this paper
• NIH plans to enhance reproducibility

  2014cited by this paper
• Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues

  2014cited by this paper
• Developing novel blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• Novel plasma biomarker surrogating cerebral amyloid deposition

  2014cited by this paper
• A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study

  2014cited by this paper
• Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.

  2014cited by this paper
• Policy: NIH plans to enhance reproducibility

  2014cited by this paper
• Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

  2014cited by this paper
• Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

  2014cited by this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard.

  2013cited by this paper
• 2013 Alzheimer's disease facts and figures

  2013cited by this paper
• Plasma tau levels in Alzheimer's disease

  2013cited by this paper
• Blood and plasma-based proteomic biomarker research in Alzheimer's disease.

  2013cited by this paper
• Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study

  2013cited by this paper
• Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study

  2013cited by this paper
• The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines

  2012cited by this paper
• Application of commercial research-grade biomarker assays in drug development: is it time to create 'pharmaceutical-grade' kits?

  2012cited by this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cited by this paper
• Believe it or not: how much can we rely on published data on potential drug targets?

  2011cited by this paper
• Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

  2011cited by this paper
• Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

  2011cited by this paper
• Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease.

  2010cited by this paper
• Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

  2010cited by this paper
• Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment

  2009cited by this paper
• Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels

  2009cited by this paper
• Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

  2009cited by this paper
• Drug discovery: new models for industry-academic partnerships.

  2009influential reference
• Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

  2008cited by this paper
• Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

  2006cited by this paper
• Why Most Published Research Findings Are False

  2005cited by this paper
• Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia.

  2004cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies

  2000cited by this paper
• Alzheimer Disease Biomarker Testing in Cerebrospinal Fluid: a Method to Harmonize Assay Platforms in the Absence of an Absolute Reference Standard Letter to the Editor

  year unknowncited by this paper

• LRG1 protein is a novel prognostic indicator for patients with non-small cell lung cancer

  2026cites this paper
• Progress in Defining Blood Biomarkers for Alzheimer's Disease Based on Biochemical Mass Spectrometry Platforms

  2026cites this paper
• Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions

  2026cites this paper
• Proximity ligation dependent immuno-PCR assay for sub-pg/mL quantification of protein biomarker

  2026cites this paper
• The association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adults

  2026cites this paper
• Targeted isolation of astrocyte-derived extracellular vesicles using peptide-imprinted nanocomposites for neurological diagnostics

  2026cites this paper
• An on-board journey from conventional to novel biomarkers for detection and monitoring of Alzheimer’s disease

  2026cites this paper
• Elevated BACE1 mRNA Level is Associated with Lower miR-15a-5p and miR-19b-3p Expressions in Peripheral Blood Mononuclear Cells of Patients with Late-Onset Alzheimer’s Disease: Wet Lab Results and Bioinformatics Analysis

  2025cites this paper
• “Advances in biomarker discovery and diagnostics for alzheimer’s disease”

  2025cites this paper
• Development and validation of an interpretable clinical scoring model to monitor the progression of preclinical Alzheimer’s disease

  2025cites this paper
• Precision exercise in older adults with early Alzheimer’s disease: The study protocol of the FIT-AD Sequential, Multiple Assignment, Randomized Trial (SMART)

  2025cites this paper
• Relationship periodontitis and Alzheimer's disease: Relevant aspects from an epigenetic view

  2025cites this paper
• Enteric nervous system dysfunction as a driver of central nervous system disorders: The Forgotten brain in neurological disease.

  2025cites this paper
• Associations of plasma biomarkers with cerebral perfusion and structure in Alzheimer’s disease

  2025cites this paper
• Microglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions.

  2025cites this paper
• A panel of altered blood oxysterols in patients with mild cognitive impairment: A novel combined diagnostic marker.

  2025cites this paper
• Markers of biological age in dogs.

  2025cites this paper
• Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

  2025cites this paper
• Older Amyloid Beta as a Candidate Blood Biomarker of Early Cognitive Decline in the Elderly—A Preliminary Study

  2025cites this paper
• The Role of Blood-Based Biomarkers in Transforming Alzheimer’s Disease Research and Clinical Management: A Review

  2025cites this paper
• The diagnostic value of plasma Aβ42 and Aβ40 in Alzheimer’s disease: current status, challenges, and impacting variables

  2025cites this paper
• Molecular pathways and biomarkers associated with age-related cognitive decline

  2025cites this paper
• Generalizability of tau and amyloid plasma biomarkers in Alzheimer's disease cohorts of diverse genetic ancestries

  2025cites this paper
• The Clinical Aspects of COVID and Alzheimer’s Disease: A Round-Up of Where Things Stand and Are Headed

  2024cites this paper
• Generalizability of Tau and Amyloid Plasma Biomarkers in Alzheimer’s Disease Cohorts of Diverse Genetic Ancestries

  2024cites this paper
• Unraveling the Tau Puzzle: A Brief Discussion on Biomarkers in Alzheimer’s Disease

  2024cites this paper
• The emerging role of brain neuroinflammatory responses in Alzheimer’s disease

  2024cites this paper
• A Critical Appraisal of Blood-Based Biomarkers for Alzheimer's Disease.

  2024cites this paper
• Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation.

  2024cites this paper
• Cognitive trajectories preluding the onset of different dementia entities: a descriptive longitudinal study using the NACC database

  2024cites this paper
• Nanomodulators That Target Alzheimer’s Disease: A Review

  2024cites this paper
• Biosensors and biomarkers: A dynamic duo towards Alzheimer's disease detection

  2024cites this paper
• Personalized use of ketamine and esketamine for treatment-resistant depression

  2024cites this paper
• Multi‐proteomic analyses of 5xFAD mice reveal new molecular signatures of early‐stage Alzheimer's disease

  2024cites this paper
• Advancing the early detection of canine cognitive dysfunction syndrome with machine learning-enhanced blood-based biomarkers

  2024cites this paper
• Discovery of plasma biomarkers related to blood-brain barrier dysregulation in Alzheimer’s disease

  2024cites this paper
• Biomarkers for Assessing Diet-Related Neurocognitive Deficits in Children—A Systematic Review

  2024cites this paper
• Highly sensitive blood-based biomarkers detection of beta-amyloid and phosphorylated-tau181 for Alzheimer’s disease

  2024cites this paper
• Emerging Biomarkers for Early Detection of Alzheimer's Disease: A Systematic Review

  2024cites this paper
• Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications

  2024cites this paper
• Kallikrein-related peptidase's significance in Alzheimer's disease pathogenesis: A comprehensive survey.

  2024cites this paper
• Agmatine as a Novel Intervention for Alzheimer's Disease: Pathological Insights and Cognitive Benefits.

  2024cites this paper
• The Current Status and Challenges of Olfactory Dysfunction Study in Alzheimer's Disease.

  2024cites this paper
• Gut Microbiota and Aging: Traditional Chinese Medicine and Modern Medicine

  2023cites this paper
• Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice

  2023cites this paper
• Cognitive Performance and Incident Alzheimer’s Dementia in Men Versus Women

  2023cites this paper
• Everyday Driving and Plasma Biomarkers in Alzheimer’s Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit

  2023cites this paper
• A Blood Screening Test for Dementia with Lewy Bodies for Primary Care

  2023cites this paper
• Proteomic Applications and Considerations: From Research to Patient Care.

  2023cites this paper
• Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers

  2023cites this paper
• The QPLEX™ Plus Assay Kit for the Early Clinical Diagnosis of Alzheimer’s Disease

  2023cites this paper
• Salivary levels of disease-related biomarkers in the early stages of Parkinson’s and Alzheimer’s disease: A cross-sectional study

  2023cites this paper
• Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease

  2023cites this paper
• Digital phenotyping: An equal opportunity approach to reducing disparities in Alzheimer's disease and related dementia research

  2023cites this paper
• Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial

  2023cites this paper
• Analyzer-to-Analyzer Variations in Assaying Ultralow Concentrated Biomarkers Associated with Neurodegenerative Diseases Using Immunomagnetic Reduction

  2023cites this paper
• Optimized RT-qPCR and a novel normalization method for validating circulating miRNA biomarkers in ageing-related diseases

  2023cites this paper
• Evaluation of Cognitive and Physical Function Among Older Adults by Their Physical Activity: A Cross-Sectional Kasama Study, Japan

  2023cites this paper
• Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease

  2023cites this paper
• The role of mitochondrial dynamics in disease

  2023cites this paper
• Early detection of Alzheimer's disease by measuring amyloid beta-42 concentration in human serum based on Liquid crystals

  2023cites this paper
• Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer’s Disease in the HABS-HD Study

  2023cites this paper
• Improving Clinical Trials of Antioxidants in Alzheimer’s Disease

  2023cites this paper
• SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis

  2023cites this paper
• Biomarkers and Risk Assessment of Alzheimer’s Disease in Low- and Middle-Income Countries

  2023cites this paper
• Ultra-sensitive SERS detection of Aβ 1–42 for Alzheimer's disease using graphene oxide/gold nanohybrids

  2023cites this paper
• Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology

  2023cites this paper
• The Role of Clinical Assessment in the Era of Biomarkers

  2023cites this paper
• Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET

  2023cites this paper
• Nurse-led pre-test counseling for Alzheimer’s disease biomarker testing: Knowledge and skills required to meet the needs of patients and families

  2023cites this paper
• Learning potential and visuospatial memory could predict amyloid-beta positron emission tomography positivity in amnestic mild cognitive impairment.

  2023cites this paper
• Parkinson’s Disease Blood Test for Primary Care

  2022cites this paper
• MicroRNA super-resolution imaging in blood for Alzheimer’s disease

  2022cites this paper
• Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status

  2022cites this paper
• The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

  2022cites this paper
• Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools

  2022cites this paper
• Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort

  2022cites this paper
• Biomarkers for dementia in Latin American countries: Gaps and opportunities

  2022cites this paper
• Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

  2022cites this paper
• Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening

  2022cites this paper
• Performance of plasma phosphorylated tau 181 and 217 in the community

  2022cites this paper
• Advances in the development of new biomarkers for Alzheimer’s disease

  2022cites this paper
• Decreased Vessel Density in Retinal Capillary Plexus and Thinner Ganglion Cell Complex Associated With Cognitive Impairment

  2022cites this paper
• Effect of Time to Detection on the Measured Concentrations of Blood Proteins Associated with Alzheimer's Disease

  2022cites this paper
• Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases

  2022cites this paper
• Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia

  2022cites this paper
• Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.

  2022cites this paper
• BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

  2022cites this paper
• Kappa/Lambda light-chain typing in Alzheimer's Disease.

  2022cites this paper
• Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer’s Disease

  2022cites this paper
• Highly sensitive surface-enhanced Raman scattering-based immunosensor incorporating half antibody-fragment for quantitative detection of Alzheimer's disease biomarker in blood.

  2022cites this paper
• Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?

  2022cites this paper
• Progress of Nanotechnology-Based Detection and Treatment of Alzheimer’s Disease Biomarkers

  2022cites this paper
• Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide

  2022cites this paper
• Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease

  2022cites this paper
• Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

  2022cites this paper
• Different techniques for Alzheimer’s disease classification using brain images: a study

  2021cites this paper
• GPS driving: a digital biomarker for preclinical Alzheimer disease

  2021cites this paper
• Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

  2021cites this paper
• Microfluidic Platforms to Unravel Mysteries of Alzheimer’s Disease: How Far Have We Come?

  2021cites this paper